BERKELEY, Calif. — September 30, 2025 — Leads & Copy — Mainz Biomed N.V. (NASDAQ:MYNZ) will present findings from its ongoing work in RNA-based diagnostics at the World Endoscopy Organization (WEO) Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions on October 3, 2025, in Berlin, Germany.
Dr. Lena Krammes, Senior Scientist at Mainz Biomed, will present clinical data from the eAArly DETECT study, highlighting stool RNA testing’s potential to identify colorectal cancer and precancerous lesions. Key findings include 97% sensitivity and specificity for detecting colorectal cancer, 82% sensitivity for advanced adenomas, and 100% detection of advanced adenomas with high-grade dysplasia.
The company’s participation reflects its commitment to improving CRC screening outcomes. Guido Baechler, CEO of Mainz Biomed, said the invitation to join the expert discussions reinforces the company’s belief that it is making important contributions toward developing effective, next-generation screening tools that can prevent colorectal cancer before it starts.
Contact Information:
Maximilian Schur / Simone Neeten
MC Services AG
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com
Source: Mainz Biomed
